Study of TGD001 for blood clotting disorders
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests a new medicine called TGD001 for people with a group of rare blood disorders called thrombotic microangiopathies (TMAs), where small blood clots form and damage organs. The goal is to see if TGD001 can help stop the clotting and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You are currently having symptoms of a thrombotic microangiopathy (TMA) episode.
- You are willing to use effective birth control for 90 days after the last dose if you are able to become pregnant or father a child.
- You do not have another condition that explains your low platelets and anemia.
- You have not had therapeutic plasma exchange (a blood-cleaning treatment) in the last 7 days.
- You do not have active bleeding or a high risk of bleeding, and you are not taking blood thinners.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how two immune system proteins, interferon and complement, are involved in a rare condition called thrombotic microangiopathy (TMA) that can damage small blood vessels after a stem cell or organ transplant. Understanding these proteins may help doctors find better treatments for TMA and related complications.
This study is testing a new combination of medicines—immune-suppressing drugs, caplacizumab, and plasma infusions—to treat immune-mediated TTP without standard plasma exchange. It aims to make treatment simpler and potentially safer.
This study looks at signs of a clotting problem in tiny blood vessels (called TMA) that can affect kidney function. The goal is to better understand the role of the body’s complement system and how it relates to different causes of this illness.
This trial looks for proteins in the blood that could help detect transplant-related blood vessel damage (called TMA) earlier, so doctors can treat it faster. It involves patients who have had a stem cell transplant from a donor.
This study looks at people who have a blood clotting problem called TMA after a stem cell transplant from a donor. It gathers information from routine checkups to learn more about this condition.
This trial tests whether taking aspirin daily can help prevent the blood-clotting episodes (called TTP) caused by a severe lack of a specific protein in your blood. If you have a history of TTP or a genetic form that increases your risk, this study may help reduce those dangerous episodes.
Hear when a new Thrombotic Microangiopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.